Picture BIO Deutschland Corona Special Germany 2020 650x80px
Organisation › Details

Genmab A/S (CSE: GEN, Nasdaq: GMAB)

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base includes a number of proprietary next generation antibody technologies Genmab has alliances with other leading pharmaceutical and biotechnology companies. *


Period Start 1999-01-01 established
  Group Genmab (Group)
Products Industry DuoBody technology platform (bispecific antibodies)
  Industry 2 Darzalex®
Person Person van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
Region Region København (Copenhagen)
  Country Denmark
  Street 43 Kalvebod Brygge
  City 1560 Copenhagen V
  Tel +45-70-202728
    Address record changed: 2019-07-14
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency DKK
  Annual sales 3,040,539,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 1,472,141,000 (2018-12-31)
  Cash 478,190,000 (2018-12-31)
    * Document for �About Section�: Genmab A/S. (7/12/19). "Press Release: Genmab and Blink Biomedical Enter into Commercial License Agreement". Copenhagen.
Record changed: 2020-04-03


Picture [LSE] – The Business Web Portal 650x65px

More documents for Genmab (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Made Without Love 650x80px

» top